Suppr超能文献

血清微小RNA作为甲状腺癌诊断和预后的生物标志物:文献综述

Serum miRNAs as Biomarkers for the Diagnosis and Prognosis of Thyroid Cancer: A Comprehensive Review of the Literature.

作者信息

Mahmoudian-Sani Mohammad-Reza, Mehri-Ghahfarrokhi Ameneh, Asadi-Samani Majid, Mobini Gholam-Reza

机构信息

Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.

Department of Genetics and Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.

出版信息

Eur Thyroid J. 2017 Jul;6(4):171-177. doi: 10.1159/000468520. Epub 2017 Apr 7.

Abstract

BACKGROUND/OBJECTIVES: Thyroid cancer is the most common endocrine malignancy and accounts for 1% of cancers. In recent years, there has been much interest in the feasibility of using miRNAs or miRNA panels as biomarkers for the diagnosis of thyroid cancer. miRNAs are noncoding RNAs with 21-23 nucleotides that are highly conserved during evolution. They have been proposed as regulators of gene expression, apoptosis, cancer, and cell growth and differentiation.

METHODS

The Directory of Open Access Journals (DOAJ), Google Scholar, PubMed (NLM), LISTA (EBSCO), and Web of Science were searched.

RESULTS

The serum level of miRNAs (miRNA-375, 34a, 145b, 221, 222, 155, Let-7, 181b) can be used as molecular markers for the diagnosis and prognosis of thyroid cancer in the serum samples of patients with thyroid glands.

CONCLUSIONS

Given that most common methods for the screening of thyroid cancer cannot detect the disease in its early stages, identifying miRNAs that are released in the bloodstream during the gradual progression of the disease is considered a key method in the early diagnosis of thyroid cancers.

摘要

背景/目的:甲状腺癌是最常见的内分泌恶性肿瘤,占所有癌症的1%。近年来,人们对使用微小RNA(miRNA)或miRNA组合作为甲状腺癌诊断生物标志物的可行性产生了浓厚兴趣。miRNA是具有21 - 23个核苷酸的非编码RNA,在进化过程中高度保守。它们被认为是基因表达、细胞凋亡、癌症以及细胞生长和分化的调节因子。

方法

检索了开放获取期刊目录(DOAJ)、谷歌学术、PubMed(美国国立医学图书馆)、LISTA(EBSCO)和科学引文索引。

结果

miRNA(miRNA - 375、34a、145b、221、222、155、Let - 7、181b)的血清水平可作为甲状腺患者血清样本中甲状腺癌诊断和预后的分子标志物。

结论

鉴于甲状腺癌最常见的筛查方法无法在疾病早期检测到该疾病,识别在疾病逐渐发展过程中释放到血液中的miRNA被认为是甲状腺癌早期诊断的关键方法。

相似文献

2
MicroRNAs in endocrine tumors.
EJIFCC. 2019 Jun 24;30(2):146-164. eCollection 2019 Jun.
3
MicroRNA expression profile of thyroid nodules in fine-needle aspiration cytology: a confirmatory series.
J Endocrinol Invest. 2019 Jan;42(1):97-100. doi: 10.1007/s40618-018-0880-6. Epub 2018 Mar 24.
5
Causes and Consequences of MicroRNA Dysregulation Following Cerebral Ischemia-Reperfusion Injury.
CNS Neurol Disord Drug Targets. 2019;18(3):212-221. doi: 10.2174/1871527318666190204104629.
6
Dermatological diseases in patients with chronic kidney disease.
J Nephropathol. 2013 Apr;2(2):104-9. doi: 10.12860/JNP.2013.17. Epub 2013 Apr 1.
7
Total circulating cell-free miRNA in plasma as a predictive biomarker of the thyroid diseases.
J Cell Biochem. 2019 Jun;120(6):9016-9022. doi: 10.1002/jcb.28173. Epub 2018 Dec 2.
9
The value of miRNA in diagnosing thyroid cancer: a systematic review.
Cancer Biomark. 2012;11(6):229-38. doi: 10.3233/CBM-2012-0273.
10
The role of microRNAs in different types of thyroid carcinoma: a comprehensive analysis to find new miRNA supplementary therapies.
J Endocrinol Invest. 2018 Mar;41(3):269-283. doi: 10.1007/s40618-017-0735-6. Epub 2017 Jul 31.

引用本文的文献

3
Opportunities and Challenges of Liquid Biopsy in Thyroid Cancer.
Int J Mol Sci. 2021 Jul 19;22(14):7707. doi: 10.3390/ijms22147707.
6
Noncoding RNAs in Extracellular Fluids as Cancer Biomarkers: The New Frontier of Liquid Biopsies.
Cancers (Basel). 2019 Aug 14;11(8):1170. doi: 10.3390/cancers11081170.
8
Downregulation of miR‑486‑5p in papillary thyroid carcinoma tissue: A study based on microarray and miRNA sequencing.
Mol Med Rep. 2018 Sep;18(3):2631-2642. doi: 10.3892/mmr.2018.9247. Epub 2018 Jul 3.

本文引用的文献

1
2
Non-Coding RNAs in Thyroid Cancer.
Endocr Pathol. 2016 Mar;27(1):12-20. doi: 10.1007/s12022-016-9417-8.
3
The evaluation of miRNAs on thyroid FNAC: the promising role of miR-375 in follicular neoplasms.
Endocrine. 2016 Dec;54(3):723-732. doi: 10.1007/s12020-016-0866-0. Epub 2016 Jan 27.
4
Over-expression of microRNA-375 inhibits papillary thyroid carcinoma cell proliferation and induces cell apoptosis by targeting ERBB2.
J Pharmacol Sci. 2016 Feb;130(2):78-84. doi: 10.1016/j.jphs.2015.12.001. Epub 2015 Dec 12.
6
Expression profiles of pivotal microRNAs and targets in thyroid papillary carcinoma: an analysis of The Cancer Genome Atlas.
Onco Targets Ther. 2015 Aug 26;8:2271-7. doi: 10.2147/OTT.S85753. eCollection 2015.
7
Serum microRNA profiling to distinguish papillary thyroid cancer from benign thyroid masses.
J Otolaryngol Head Neck Surg. 2015 Sep 5;44(1):33. doi: 10.1186/s40463-015-0083-5.
8
MicroRNAs in Cancer: A Historical Perspective on the Path from Discovery to Therapy.
Cancers (Basel). 2015 Jul 27;7(3):1388-405. doi: 10.3390/cancers7030842.
9
Down-regulation of miR-181b promotes apoptosis by targeting CYLD in thyroid papillary cancer.
Int J Clin Exp Pathol. 2014 Oct 15;7(11):7672-80. eCollection 2014.
10
Association between a functional polymorphism rs712 within let-7-binding site and risk of papillary thyroid cancer.
Med Oncol. 2014 Oct;31(10):221. doi: 10.1007/s12032-014-0221-3. Epub 2014 Sep 9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验